开发并外部验证基于MRI的列线图评估转移性肺腺癌患者EGFR和T790M突变
本研究纳入本院160例和另一医院32例肺腺癌脊柱转移患者,提取脊柱MRI(T1W和T2FS)影像组学特征构建放射组学标签,联合吸烟状态建立列线图模型检测EGFR和T790M突变;模型在训练集、内部验证集和外部验证集中检测EGFR突变的AUC分别为0.849、0.828和0.778,检测T790M突变的AUC分别为0.842、0.823和0.800。
要点
- 脊柱转移灶MRI影像组学特征对肺腺癌EGFR及T790M突变具有预测价值。
- 联合放射组学标签与吸烟状态的列线图模型在外部验证集中检测EGFR突变AUC为0.778。
- 该列线图模型在外部验证集中检测T790M突变AUC为0.800。
核心结论
- 脊柱转移灶的影像组学特征对EGFR和T790M突变均有预测作用,所构建的列线图模型可能作为新的标志物指导伴脊柱转移的肺腺癌患者的治疗管理。
研究设计与样本
- 研究纳入本院2017年1月至2021年2月的160例肺腺癌患者构建主要队列,并纳入另一医院2017年1月至2021年1月的32例患者构建外部队列;所有患者接受脊柱MRI(包括T1W和T2FS)扫描,从转移灶提取影像组学特征并筛选构建放射组学标签,联合放射组学标签和重要临床参数构建临床-放射组学列线图模型,采用ROC曲线评估预测能力,并用校准曲线和决策曲线分析验证模型性能。
诊断标准与关键数值
- 检测EGFR突变时,列线图模型(包含放射组学标签和吸烟状态)在训练集、内部验证集和外部验证集的AUC分别为0.849(敏感度=0.685,特异度=0.885)、0.828(敏感度=0.964,特异度=0.692)和0.778(敏感度=0.611,特异度=0.929);检测T790M突变时,相应AUC分别为0.842(敏感度=0.750,特异度=0.867)、0.823(敏感度=0.667,特异度=0.938)和0.800(敏感度=0.875,特异度=0.800)。
临床应用与阅片要点
- 作者认为,基于脊柱转移灶的列线图模型可能作为检测EGFR和T790M突变的潜在新标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study aims to explore values of multi-parametric MRI-based radiomics for detecting the epidermal growth factor receptor (EGFR) mutation and resistance (T790M) mutation in lung adenocarcinoma (LA) patients with spinal metastasis.
METHODS: This study enrolled a group of 160 LA patients from our hospital (between Jan. 2017 and Feb. 2021) to build a primary cohort. An external cohort was developed with 32 patients from another hospital (between Jan. 2017 and Jan. 2021). All patients underwent spinal MRI (including T1-weighted (T1W) and T2-weighted fat-suppressed (T2FS)) scans. Radiomics features were extracted from the metastasis for each patient and selected to develop radiomics signatures (RSs) for detecting the EGFR and T790M mutations. The clinical-radiomics nomogram models were constructed with RSs and important clinical parameters. The receiver operating characteristics (ROC) curve was used to evaluate the predication capabilities of each model. Calibration and decision curve analyses (DCA) were constructed to verify the performance of the models.
RESULTS: For detecting the EGFR and T790M mutation, the developed RSs comprised 9 and 4 most important features, respectively. The constructed nomogram models incorporating RSs and smoking status showed favorite prediction efficacy, with AUCs of 0.849 (Sen = 0.685, Spe = 0.885), 0.828 (Sen = 0.964, Spe = 0.692), and 0.778 (Sen = 0.611, Spe = 0.929) in the training, internal validation, and external validation sets for detecting the EGFR mutation, respectively, and with AUCs of 0.0.842 (Sen = 0.750, Spe = 0.867), 0.823 (Sen = 0.667, Spe = 0.938), and 0.800 (Sen = 0.875, Spe = 0.800) in the training, internal validation, and external validation sets for detecting the T790M mutation, respectively.
CONCLUSIONS: Radiomics features from the spinal metastasis were predictive on both EGFR and T790M mutations. The constructed nomogram models can be potentially considered as new markers to guild treatment management in LA patients with spinal metastasis.
KEY POINTS: • To our knowledge, this study was the first approach to detect the EGFR T790M mutation based on spinal metastasis in patients with lung adenocarcinoma. • We identified 13 MRI features that were strongly associated with the EGFR T790M mutation. • The proposed nomogram models can be considered as potential new markers for detecting EGFR and T790M mutations based on spinal metastasis.
引用
- Fan, Dong, Wang, et al. Development and externally validate MRI-based nomogram to assess EGFR and T790M mutations in patients with metastatic lung adenocarcinoma. Eur Radiol. 2022. PMID: 35729427. doi:10.1007/s00330-022-08955-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。